Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 8/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 8/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12456445 | 0.87 | CDK1 (0.35) | CDK1CCNB1CCNE1CDK2MAPKAPK2 | |
| SCHEMBL27112701 | 0.83 | SRC (0.35) | — | |
| SCHEMBL10268684 | 0.80 | CDK1 (0.38) | CDK1CCNB1CCNE1CDK2MAPKAPK2 | |
| SCHEMBL10212549 | 0.80 | MAPKAPK2 (0.44) | DHFRP2RX3P2RX2MAPKAPK2 | |
| SCHEMBL12393901 | 0.70 | MAPKAPK2 (0.41) | MAPKAPK2 | |
| SCHEMBL21663044 | 0.69 | PIK3CD (0.36) | DHFRP2RX3P2RX2 | |
| SCHEMBL27112892 | 0.68 | LRRK2 (0.32) | CDK1CCNB1CCNE1CDK2 | |
| SCHEMBL19733383 | 0.68 | ADORA2A (0.47) | CDK1CCNB1CCNE1CDK2 | |
| SCHEMBL27112774 | 0.66 | SRC (0.39) | CDK1CCNB1CCNE1CDK2 | |
| SCHEMBL24797317 | 0.65 | CDK1 (0.33) | CDK1CCNB1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | DHFR 344/4885CDK1 540/4885CCNB1 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.